Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 8.3% in the afternoon session after the company reported fourth-quarter revenue that missed Wall Street's ...

Q4 2025 Management View CEO Robert Ford highlighted that 2025 showcased "Abbott's leadership in innovation, disciplined execution and strategic actions taken to position the company for sustainable ...

Abbott’s stock has fallen by over 7% despite reporting strong fiscal year 2025 (FY25) revenues of $44.32bn, representing a ...

Abbott Communications finally launched on Y&R, and it's still completely pointless. What exactly is Sally Spectra even the ...

The company's full-year 2025 revenues rose 6 percent year over year, with a 4 percent decline in diagnostics for the year.

The medical device maker announced it anticipates first quarter adjusted profits per share between $1.12 and $1.18, trailing ...

Pricing challenges in Abbott’s nutrition business and lower than expected sales of continuous glucose monitors drove down the ...

European shares were higher today. The eurozone's STOXX 600 gained 1.09%, while Spain's IBEX 35 Index rose 1.01%. London's FTSE 100 rose 0.26%, Germany's DAX gained 1.19% and France's CAC 40 gained ...

US stocks extended gains on President Donald Trump’s retreat from tariff threats while traders’ appetite for artificial ...

Abbott Laboratories stock has reached a 52-week low, closing at $107.27. This marks a notable point for the healthcare company, as it navigates a challenging market environment. Over the past year, ...

Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%. Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80 and first-quarter 2026 ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...